CHENGDU, China , Oct. 11, 2025 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner, Biokin Pharmaceutical , on receiving implied approval from the National Medical Products Administration (NMPA) for the clinical trial application of [ 177 Lu]-BL-ARC001 Injection , the company's first radiopharmaceutical and a Class 1 innovative biologic.

This milestone approval marks Biokin's entry into the fast-growing Radiopharmaceutical Drug Conjugate (RDC) field and reinforces its leadership in large-molecule oncology therapies (ADC/GNC/ARC). The company's flagship asset BL-B01D1 (a first-in-class EGFR×HER3 bispecific ADC) set a record-breaking global licensing deal of USD 8.4 billion , underscoring Biokin's innovation strength and global v

See Full Page